Scutellarein Inhibits Osteosarcoma Growth by Targeting the TLR4/TRAF6/NF-κB Pathway

Drug Design Development and Therapy, Год журнала: 2025, Номер Volume 19, С. 51 - 64

Опубликована: Янв. 1, 2025

Osteosarcoma (OS) is the most common malignant tumor associated with poor patient outcomes and a limited availability of therapeutic agents. Scutellarein (SCU) monomeric flavone bioactive compound potent anti-cancer activity. However, effects mechanisms SCU on growth OS remain unknown. The Cell Counting Kit-8, colony formation assay 5-ethynyl-2'-deoxyuridine (EdU) incorporation assays were used to analyze cell proliferation ability in vitro. TLR4/TRAF6/NF-κB signaling transduction was investigated by RNA sequencing analysis, quantitative real-time polymerase chain reaction, Western blotting, NF-κB luciferase reporter assay, immunofluorescent staining, immunoprecipitation. Molecular docking cellular thermal shift employed confirm binding interaction between TLR4. TLR4 overexpression analyzed using xenograft model immunohistochemical staining. found significantly inhibit proliferation, analysis suggested that pathway closely this process. Further studies revealed inhibited canonical through its TLR4, which disrupted TRAF6. Moreover, also repressed signal inhibiting expression. Furthermore, suppress targeting vitro vivo. exhibited dual impact expression disrupting TLR4-TRAF6 interaction, resulting inactivation, thereby blocking growth.

Язык: Английский

---

Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials

Biomedicines, Год журнала: 2025, Номер 13(3), С. 664 - 664

Опубликована: Март 8, 2025

Osteosarcoma (OS) is the predominant mesenchymal primary malignant bone tumor in oncology and pathology, impacting a wide age range from adolescents to older adults. It frequently advances lung metastasis, ultimately resulting mortality of OS patients. The precise pathological pathways responsible for progression dissemination are not fully understood due its heterogeneity. integration surgery with neoadjuvant postoperative chemotherapy has significantly increased 5-year survival rate more than 70% patients localized tumors. However, about 30% experience local recurrence and/or metastasis. Hence, there requirement innovative therapeutic approaches address limitations traditional treatments. Immunotherapy garnered increasing attention as promising avenue tumors resistant standard therapies, including OS, despite underlying mechanisms disease remaining well elucidated. may have been suitable use because tumor’s immunosuppressive microenvironment limited immunogenicity. Nevertheless, immune-based treatments now being developed clinical use, such bispecific antibodies, chimeric antigen receptor T cells, immune checkpoint inhibitors. Also, additional immunotherapy techniques cytokines, vaccines, modified-Natural Killer (NK) cells/macrophages early phases research but will certainly be popular subjects nearest future. Our goal writing this review was spark new lines inquiry into by summarizing findings both preclinical current studies examining different approaches.

Язык: Английский

---

Activation of pyroptosis and immunogenic cell death by targeted liposomal cisplatin for enhanced chemo-immunotherapy for osteosarcoma

Nano Today, Год журнала: 2025, Номер 62, С. 102717 - 102717

Опубликована: Март 19, 2025

Язык: Английский

---

Local drug delivery challenges and innovations in spinal neurosurgery

Journal of Controlled Release, Год журнала: 2024, Номер 376, С. 1225 - 1250

Опубликована: Ноя. 12, 2024

Язык: Английский

---

Reprogramming the melanoma and immunosuppressive myeloid cells with esomeprazole-loaded PLGA nanoparticles

iScience, Год журнала: 2024, Номер 28(1), С. 111559 - 111559

Опубликована: Дек. 9, 2024

Язык: Английский

---